Cargando…
Drug-induced liver injury in COVID-19 patients during hospitalization
Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, an...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018522/ https://www.ncbi.nlm.nih.gov/pubmed/36930097 http://dx.doi.org/10.1097/MD.0000000000033294 |
_version_ | 1784907827559530496 |
---|---|
author | Chen, Ying Shi, Cai Zhan, Haiyan Yang, Boning Liu, Jun Rong, Peipei Luo, Yi Yang, Jian |
author_facet | Chen, Ying Shi, Cai Zhan, Haiyan Yang, Boning Liu, Jun Rong, Peipei Luo, Yi Yang, Jian |
author_sort | Chen, Ying |
collection | PubMed |
description | Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, and further to explore DILI in COVID-19 patients during hospitalization. It was a single-center retrospective analysis of confirmed severe acute respiratory syndrome coronavirus 2 infected patients in the hospital from January 2020 to March 2020. Univariate and multivariate logistic regression analysis were used to assess the risk factors associated with liver test abnormality or liver injury. At admission, 148 (48.8%, 148/303) patients had abnormal liver test results and 7 (2.4%, 7/303) had liver injury, while 195 (64.4%, 195/303) had abnormal liver test results and 17 (5.6%, 17/303) had liver injury during hospitalization. After excluding these patients with liver disease and liver function abnormalities or liver injury at admission, 15 (11.1%, 15/135) patients developed DILI during hospitalization. Further regression analysis indicated that methylprednisolone (odds ratio = 4.177, 95% confidence interval [1.106–15.771], P = .035), but not Chinese herbal medicine or other used drug, was associated with DILI in patients during hospitalization. Abnormal liver function results were in more than half of patients with COVID-19, and the incidence of DILI in COVID-19 patients was 11.1% during hospitalization. Liver test abnormality or liver injury in patients might be directly caused by the viral infection at admission, but the detrimental effects on liver injury mainly related to certain medications used during hospitalization, particularly methylprednisolone. Severe COVID-19 could increase the occurrence of liver injury (P = .007) during hospitalization, but not a risk factor of liver injury. However, Chinese herbal medicine was a protective factor for liver injury. |
format | Online Article Text |
id | pubmed-10018522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100185222023-03-17 Drug-induced liver injury in COVID-19 patients during hospitalization Chen, Ying Shi, Cai Zhan, Haiyan Yang, Boning Liu, Jun Rong, Peipei Luo, Yi Yang, Jian Medicine (Baltimore) 4200 Since coronavirus disease 2019 (COVID-19) outbreaks in December 2019 in Wuhan, almost no studies have systematically described drug-induced liver injury (DILI) in COVID-19 patients. This study aimed to assess the characteristics of liver test abnormality or liver injury in patients with COVID-19, and further to explore DILI in COVID-19 patients during hospitalization. It was a single-center retrospective analysis of confirmed severe acute respiratory syndrome coronavirus 2 infected patients in the hospital from January 2020 to March 2020. Univariate and multivariate logistic regression analysis were used to assess the risk factors associated with liver test abnormality or liver injury. At admission, 148 (48.8%, 148/303) patients had abnormal liver test results and 7 (2.4%, 7/303) had liver injury, while 195 (64.4%, 195/303) had abnormal liver test results and 17 (5.6%, 17/303) had liver injury during hospitalization. After excluding these patients with liver disease and liver function abnormalities or liver injury at admission, 15 (11.1%, 15/135) patients developed DILI during hospitalization. Further regression analysis indicated that methylprednisolone (odds ratio = 4.177, 95% confidence interval [1.106–15.771], P = .035), but not Chinese herbal medicine or other used drug, was associated with DILI in patients during hospitalization. Abnormal liver function results were in more than half of patients with COVID-19, and the incidence of DILI in COVID-19 patients was 11.1% during hospitalization. Liver test abnormality or liver injury in patients might be directly caused by the viral infection at admission, but the detrimental effects on liver injury mainly related to certain medications used during hospitalization, particularly methylprednisolone. Severe COVID-19 could increase the occurrence of liver injury (P = .007) during hospitalization, but not a risk factor of liver injury. However, Chinese herbal medicine was a protective factor for liver injury. Lippincott Williams & Wilkins 2023-03-17 /pmc/articles/PMC10018522/ /pubmed/36930097 http://dx.doi.org/10.1097/MD.0000000000033294 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 4200 Chen, Ying Shi, Cai Zhan, Haiyan Yang, Boning Liu, Jun Rong, Peipei Luo, Yi Yang, Jian Drug-induced liver injury in COVID-19 patients during hospitalization |
title | Drug-induced liver injury in COVID-19 patients during hospitalization |
title_full | Drug-induced liver injury in COVID-19 patients during hospitalization |
title_fullStr | Drug-induced liver injury in COVID-19 patients during hospitalization |
title_full_unstemmed | Drug-induced liver injury in COVID-19 patients during hospitalization |
title_short | Drug-induced liver injury in COVID-19 patients during hospitalization |
title_sort | drug-induced liver injury in covid-19 patients during hospitalization |
topic | 4200 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018522/ https://www.ncbi.nlm.nih.gov/pubmed/36930097 http://dx.doi.org/10.1097/MD.0000000000033294 |
work_keys_str_mv | AT chenying druginducedliverinjuryincovid19patientsduringhospitalization AT shicai druginducedliverinjuryincovid19patientsduringhospitalization AT zhanhaiyan druginducedliverinjuryincovid19patientsduringhospitalization AT yangboning druginducedliverinjuryincovid19patientsduringhospitalization AT liujun druginducedliverinjuryincovid19patientsduringhospitalization AT rongpeipei druginducedliverinjuryincovid19patientsduringhospitalization AT luoyi druginducedliverinjuryincovid19patientsduringhospitalization AT yangjian druginducedliverinjuryincovid19patientsduringhospitalization |